Cited by 627Cardiac Fibrosis and RemodelingHeart Failure Treatment and ManagementInflammation biomarkers and pathways

Inflammatory mediators in chronic heart failure: an overview

Open access
Anker, Stefan D, von Haehling, Stephan·2004·Heart

Abstract

hronic heart failure (CHF) represents a major public health burden, and its prognosis is comparable to that of different malignant diseases.Our understanding of CHF has developed from the rather simplistic model of mere pump failure to that of a multisystem disorder which affects not only the cardiovascular system but also the musculoskeletal, renal, neuroendocrine, and immune systems.Thus, the pathophysiology of CHF is exceedingly complex.Therapies to block excessive neuroendocrine activation have become a cornerstone of treatment.CHF progresses because of activation of neurohormones and pro-inflammatory cytokines following an initial cardiac injury or a mutation of the genetic programme.1 Virtually any heart disease can ultimately lead to heart failure, although the initial event leading to the development of this syndrome is in many cases unknown.However, CHF is always the result of some underlying process and the diagnosis cannot stand alone.The activation of the aforementioned systems maintains and worsens CHF.In particular, the activation of the immune system has received considerable interest in the last decade.There are several different components to this system which interact with each other in a complex manner.It is becoming increasingly apparent that inflammatory mediators play a crucial role in the development of CHF, and several strategies to counterbalance different aspects of the inflammatory response are considered.Possible targets involve pro-and anti-inflammatory cytokines and their receptors, endotoxin, adhesion molecules, nitric oxide and nitric oxide synthase, reactive oxygen species, and different types of leucocytes.The purpose of this review is to give a brief overview of the current understanding of the role of inflammation in CHF.Furthermore, we will discuss recent advances in the development of new therapeutic strategies in this field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/hrt.2002.007005

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In congestive heart failure, pro-inflammatory cytokines TNF, IL-6, and IL-1 are markedly elevated, and TNF level is a negative prognostic factor.

    “in patients with congestive heart failure, the levels of pro-inflammatory cytokines, especially TNF, IL-6, and IL-1, are markedly elevated, and the TNF level is a negative prognostic factor”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. c Comprehensive up-to-date review of basic science issues in the context of cytokines in heart failure.

Cited by

Sorted by citations

Authors
Anker, S. D., & von Haehling, S.
Affiliations
  • Imperial College London (GB)
  • Department of Clinical Cardiology, Imperial College School of Medicine, National Heart & Lung Institute, London, UK
Corresponding author
Anker, Stefan D
Venue
Heart
Publisher
BMJ
Published
2004-03-12
Volume
90
Issue
4
Pages
464-470
ISSN
  • 1355-6037 (ISSN-L)
  • 1468-201X
OpenAlex
W2104179458
Cited by
627
References
33
Citations by year
2026: 21 · 2025: 14 · 2024: 23 · 2023: 17 · 2022: 27 · 2021: 26 · 2020: 23 · 2019: 36 · 2018: 43 · 2017: 43 · 2016: 34 · 2015: 18 · 2014: 35 · 2013: 30 · 2012: 32
FWCI
16.81
Type
journal article
Language
en
Open access
Locations
  • Heart (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Deutsche Herzstiftung
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
chronic heart failure, inflammation, inflammatory mediators, inflammatory cytokines, anti-inflammatory cytokines, neuroendocrine activation, neurohormones, endotoxin, adhesion molecules, nitric oxide, reactive oxygen species, leukocytes, immune system, heart failure pathophysiology, anti-inflammatory therapy
MeSH terms
Etanercept, Infliximab, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, C-Reactive Protein, Heart Failure, Humans, Immunoglobulin G, Leukocytes, Myocarditis, Nitric Oxide, Tumor Necrosis Factor-alpha, Cell Adhesion Molecules, Lymphocyte Subsets, Cytokines, Receptors, Tumor Necrosis Factor, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review